Key Takeaway: The article discusses the potential anti-cachexia properties of the novel dual-MEK inhibitor IMM-1-104. However, it lacks specific details or findings related to the drug's efficacy or clinical implications. The content primarily focuses on website privacy and cookie settings rather than the drug itself.
Price reaction · baseline $2.18 (2024-12-06 close) · clean, no other IMRX news in the window
day 0 close
-1.8%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
11.4%
average across 8 past catalysts
Cash runway
~36 mo
Minimal dilution risk
Lead asset
IMM-1-104 Monotherapy
Phase 1 · Advanced Solid Tumor
Full Press Release Details
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.